{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:10:33Z","timestamp":1788898233389,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.healun.2017.11.015","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T15:47:51Z","timestamp":1510847271000},"page":"611-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era"],"prefix":"10.1016","volume":"37","author":[{"given":"Arnt V.","family":"Kristen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Kreusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-8710","authenticated-orcid":false,"given":"Patrick","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Frankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas O.","family":"D\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Helmschrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schmack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Ruhparwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo A.","family":"Katus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.J.","family":"Raake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2017.11.015_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10741-017-9601-z","article-title":"Heart transplantation in cardiac amyloidosis","volume":"22","author":"Sousa","year":"2017","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.healun.2017.11.015_bib2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2017.11.015_bib3","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2017.11.015_bib4","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2017.11.015_bib5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.healun.2017.11.015_bib6","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.healun.2017.11.015_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.healun.2017.11.015_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.healun.2014.09.006","article-title":"Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy","volume":"34","author":"Davis","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.healun.2013.09.004","article-title":"Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis","volume":"33","author":"Gilstrap","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib10","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jacc.2007.08.028","article-title":"Evaluation and management of the cardiac amyloidosis","volume":"50","author":"Selvanayagam","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2017.11.015_bib11","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","article-title":"Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure","volume":"67","author":"Sperry","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2017.11.015_bib12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.healun.2013.11.007","article-title":"Prognostic stratification and treatment of cardiac light chain amyloidosis: a narrow path in the jungle","volume":"33","author":"Potena","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib13","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/eurjhf\/hfp121","article-title":"Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis","volume":"11","author":"Kristen","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.healun.2017.11.015_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00392-006-0439-y","article-title":"Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation","volume":"95","author":"Perz","year":"2006","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.healun.2017.11.015_bib15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ajt.13025","article-title":"Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era","volume":"15","author":"Davis","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.healun.2012.10.014","article-title":"Should we avoid heart transplantation in cardiomyopathy due to radiotherapy\/chemotherapy or amyloidosis? The devil is in the details","volume":"31","author":"Nohria","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib17","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.healun.2003.08.027","article-title":"Cardiac transplantation for amyloid heart disease: the United Kingdom experience","volume":"23","author":"Dubrey","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1600-6143.2008.02162.x","article-title":"Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis","volume":"8","author":"Hamour","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib19","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.healun.2004.08.025","article-title":"Outcome of heart transplantation in patients with amyloid cardiomyopathy","volume":"24","author":"Kpodonu","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.healun.2011.09.010","article-title":"Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies","volume":"31","author":"Varr","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, April 18-22, 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.healun.2017.11.015_bib23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.healun.2017.11.015_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.healun.2008.05.016","article-title":"Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy","volume":"27","author":"Lacy","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2017.11.015_bib25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2017.11.015_bib26","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2017.11.015_bib27","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.healun.2017.11.015_bib28","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2017.11.015_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Va130Met and non-Va1122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.healun.2017.11.015_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40120-015-0031-3","article-title":"A review of tafamidis for the treatment of transthyretin-related amyloidosis","volume":"4","author":"Waddington Cruz","year":"2015","journal-title":"Neurol Ther"},{"key":"10.1016\/j.healun.2017.11.015_bib31","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1517\/13543784.2014.922541","article-title":"An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis","volume":"23","author":"Obici","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.healun.2017.11.015_bib32","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Va130Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.healun.2017.11.015_bib33","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2017.11.015_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.healun.2017.11.015_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0000000000001021","article-title":"Survival after transplantation in patients with mutations other than Va130Met: extracts from the FAP World Transplant Registry","volume":"100","author":"Suhr","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2017.11.015_bib36","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2017.11.015_bib37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249817321162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249817321162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:34:29Z","timestamp":1760949269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249817321162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1053249817321162"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2017.11.015","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2017.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}